Psoriasis

In addition to improvements in work productivity, tildrakizumab also demonstrated significant efficacy and safety.

Investigators noted that patients with mild psoriasis experience a less favorable status when compared to patients with moderate psoriasis.

PASI scores were significantly correlated with sleep quality, duration, and disturbances.

Authors of the case report that little is known about the associations between psoriasis and renal function.

The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.

Leah Howard, JD, of the National Psoriasis Foundation, discusses the importance of advocacy in psoriasis, the role of mental health in chronic skin conditions, and the role of support organizations in advocating for awareness and health equity.

Once daily application of tapinarof cream 1% rapidly improved itch in adult patients with varying plaque psoriasis diseases severity, according to a poster presented at SDPA’s fall conference.

Douglas DiRuggiero, DMSc, PA-C, presented a comprehensive session at the SDPA fall conference on treatment selection for patients with psoriasis.

Black and male patients exhibited a higher prevalence of palmoplantar psoriasis when compared with White patients.

82.8% of adult patients with iPsO achieved an IGA score of 0 or 1 indicative of complete or almost complete lesion clearance.

Topline results from the phase 3b trial revealed significant improvements in patients with skin of color whose psoriasis was treated with guselkumab.

Bimekizumab is now the first and only approved IL-17A and IL-17F inhibitor for this indication.

At week 8, 65.3% of roflumilast-treated patients achieved a clinically significant reduction in itch.

Patients and their families experienced significant improvements to well-being with tildrakizumab use in as little as 16 weeks.

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

Experts discuss the treatment landscape of generalized pustular psoriasis as well as review difficult cases of GPP.

Protagonist Therapeutics has just announced the company's eligibility to receive $60 million of milestone payments for JNJ-2113 to enter into clinical development programs led by Janssen.

The approval provides pediatric patients with a steroid-free topical therapy.

In a cohort of patients in the UK, investigators found that SARS-CoV-2 was associated with increased incidence of several immune-mediated inflammatory diseases, with psoriasis among them.

The September 2023 issue of Dermatology Times featured a spotlight on psoriasis research, advances, and treatment options in patients with skin of color. Learn more about the topics covered in each spotlight article.

Investigators reported successful treatment of psoriasis with risankizumab, despite presence of concomitant HIV infection in 4 male patients.

Raj Chovatiya, MD, PHD, and Boni Elewski, MD, discuss long-term treatment selection for a patient whose GPP flare cleared with 1 infusion of spesolimab.

Boni Elewski, MD, reviews a case of a woman in the emergency department with a severe GPP flare.

Researchers explored the relationship between psoriasis severity and its link to coronary microvascular dysfunction in the largest such study to date.

Boni Elewski, MD, shares her personal experience using generalized pustular psoriasis treatments in the clinical setting.

Drs Raj Chovatiya and Boni Elewski discuss a patient case and the challenges of diagnosing generalized pustular psoriasis (GPP), commenting on the many types of psoriasis and treatment.

FDA action is no longer expected in Q3 of 2023.

Alexa Hetzel, MS, PA-C; Jennifer Conner, MPAS, PA-C; Terry Faleye, MPAS, PA-C; Laura Bush, DMSc, PA-C; and Lakshi Aldredge, MSN, ANP-BC, share take-home messages regarding the treatment of patients with plaque psoriasis, highlighting listening to and educating patients.

Experts in dermatology review unmet needs in the plaque psoriasis treatment landscape, as well as ongoing studies coming down the pipeline.

There may be delays in diagnosis and treatment of psoriasis in patients with darker skin tones due to the clinical presentation variations and less visible erythema.